Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG1690 Extension Study in Systemic Sclerosis
NCT03976648Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Jul 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of ziritaxestat in systemic sclerosis (SSc), sponsored by Galapagos NV. Started Jul 2019; status: terminated.
02
Drugs
ziritaxestat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT03976648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976648.